findmyKOL
Clinical trialNCT02893917Active, not recruitingPhase 2Interventional

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

SponsorNational Cancer Institute (NCI)Enrollment90Advanced Prostate Adenocarcinoma With Neuroendocrine DifferentiationCastration-Resistant Prostate CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate CarcinomaProstate Adenocarcinoma With Neuroendocrine DifferentiationStage IV Prostate Adenocarcinoma AJCC v7
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Uc San Diego Moores Cancer Center

    La Jolla, California, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, United States

  • Uc San Diego Medical Center - Hillcrest

    San Diego, California, United States

  • Smilow Cancer Center/yale-New Haven Hospital

    New Haven, Connecticut, United States

  • Yale University

    New Haven, Connecticut, United States

  • Moffitt Cancer Center

    Tampa, Florida, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, United States

  • Wayne State University/karmanos Cancer Institute

    Detroit, Michigan, United States

  • Weisberg Cancer Treatment Center

    Farmington Hills, Michigan, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

  • University of Pittsburgh Cancer Institute (upci)

    Pittsburgh, Pennsylvania, United States

  • Vanderbilt University/ingram Cancer Center

    Nashville, Tennessee, United States

  • Vcu Massey Comprehensive Cancer Center

    Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 Aug 2017
Primary completion
14 Mar 2023
Completion
31 May 2027
Last update posted
16 Jun 2026
Registered enrollment
90
Registry id
NCT02893917

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.